

**Supplementary Table S1.** Direct Antiviral Agents (DDA) regimens administered to the study cohort.

<b>DAA regimens</b>	<b>N (%)</b>
Sofosbuvir/Ledipasvir (+/- Ribavirin)	200 (53.6%)
Sofosbuvir (+/- Ribavirin)	52 (13.9%)
Paritaprevir/Ritonavir/Ombitasvir + Dasabuvir (+/- Ribavirin)	42 (11.3%)
Sofosbuvir + Daclatasvir (+/- Ribavirin)	28 (7.5%)
Sofosbuvir/Velpatasvir (+/- Ribavirin)	22 (5.9%)
Sofosbuvir + Simeprevir (+/- Ribavirin)	15 (4.0%)
Paritaprevir/Ritonavir/Ombitasvir (+/- Ribavirin)	10 (2.7%)
Sofosbuvir + Velpatasvir + Voxilaprevir (+/- Ribavirin)	2 (0.5%)
Elbasvir/Grazoprevir (+/- Ribavirin)	1 (0.3%)
Glecaprevir + Pibrentasvir (+/- Ribavirin)	1 (0.3%)